Latest Us Market Expansion News

Echo IQ’s application for a key US procedural code was rejected but the company plans a swift resubmission, maintaining confidence in its US commercial rollout.

Adherium Limited has locked in $900,000 through convertible notes to fund the expansion of its Hailie® Smartinhaler® platform in the US, pending shareholder approval at the upcoming AGM.

Lumos Diagnostics has secured Medicare reimbursement for its FebriDx test from a fifth contractor, covering more than 70% of US Medicare payments and advancing its commercial reach.

HITIQ Limited has announced a non-renounceable entitlement offer to raise up to $2.92 million, supported by partial underwriting from GBA Capital and accompanied by new options issuance. The capital raise aims to fund expansion, product development, and operational growth.

Lumos Diagnostics has secured its largest single US purchase order for its rapid respiratory test FebriDx, signaling growing adoption in American healthcare settings.

Orthocell has rapidly expanded its US distributor network for Remplir™, surpassing its target ahead of schedule and positioning itself for imminent sales in the $1.6 billion nerve repair market.

Guzman y Gomez has unveiled an ambitious expansion and margin improvement plan at the 2025 Macquarie Australia Conference, reaffirming its FY25 guidance and spotlighting strong franchise growth and operational excellence.

Echo IQ has raised $17.3 million through a strongly supported institutional placement to fund US commercialization and FDA approval efforts for its EchoSolv AI cardiology products.

SciDev Limited reported a robust Q3 FY25 with revenue rising 10% and EBITDA tripling, driven by strategic US market expansion and a landmark PFAS remediation contract despite ongoing market challenges.

HITIQ Ltd has successfully completed a $680,000 placement and launched a $2.92 million rights issue, positioning the company to fund its strategic shift towards the consumer market and expand its footprint in the US.

Echo IQ Limited marked a pivotal quarter with FDA clearance for EchoSolv AS, strategic US partnerships, and a clear path toward reimbursement and broader commercialisation.

RMA Global Limited reported a robust Q3 FY25, achieving a 21% revenue increase to $5.5 million and marking its third consecutive quarter of positive operating cash flow, driven by US market expansion and the strategic acquisition of Curated Social.